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Objective/background: Fluoroquinolones (FQs) are important anti-tuberculous drugs for the
treatment of multidrug-resistant (MDR) tuberculosis. Resistance to FQs leads to fewer
options for treatment of tuberculosis (TB), and infection with such strains may also require
longer treatment duration. Trends of resistance inMycobacterium tuberculosis (MTB) are indi-
cators of MTB-resistance evolution. Drivers of such resistance need to be understood and
studied to inform preventive strategies.
Methods: Here, we present FQ-resistance rates and trends in Pakistan from 2010 to 2015 and
compare rates with FQ-consumption data and rates in other community pathogens.
Results: Our results reveal a recent decrease in FQ-resistance rates in MTB, but an increase
in resistance for Haemophilus influenzae and Shigella spp. Correlation of FQ resistance with
FQ consumption at the population level was weak for MTB, although strong associations
were noted for H. influenzae and Shigella spp.
Conclusion: We discuss the possible reasons for the decrease in resistance rates in TB, puta-
tive drivers of resistance other than volume of FQ consumption, and the possible impact of
the National Tuberculosis Programme and drug regulatory activities.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Road, P.O.
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Fluoroquinolones (FQs) are essential drugs for the treatment
of multidrug-resistant (MDR) tuberculosis (TB). Increasing
rates of resistance worldwide have sparked concerns over
the driving factors of FQ resistance in vivo and in the environ-
ment [1]. Environmental factors contributing to resistance
include residual concentration of FQs in food, water, animal
feed, and also subinhibitory concentrations of FQs used to
treat various community acquired infections [2]. This phe-
nomenon may be especially pronounced in countries with
weak healthcare systems. Such environmental stressors have
also led to increases in FQ-resistance rates in other commu-
nity pathogens, such as Salmonella spp., Shigella spp., Neisseria
gonorrhoeae, and Streptococcus pneumoniae [1]. A directly pro-
portional relationship is expected between the volume of FQ
use in the community at the population level (selective pres-
sure in the environment) and emergence, maintenance, and
rise in resistance rates of many organisms [3]. This was
demonstrated for S. pneumoniae [4], but has not been studied
in Mycobacterium tuberculosis (MTB).
We previously reported high and increasing FQ-resistance
rates among MTB isolates from all over Pakistan from 2005 to
2009 [5,6]. Here, we report subsequent resistance data and
correlate population-level FQ-consumption rates in Pakistan
with resistance trends in MTB and other pathogens.
Methods
For resistance rates and trends, laboratory records were
examined from the Aga Khan University (AKU) clinical micro-
biology laboratory from 2010 to 2015 for S. pneumoniae and
Haemophilus influenzae among respiratory pathogens, N. gonor-
rhoeae (a venereal disease pathogen), Salmonella Typhi, Sal-
monella Paratyphi, Shigella spp., and Vibrio cholerae among
gastrointestinal pathogens, where the use of FQ is common,
and for the MTB complex. The AKU clinical laboratories
received samples on physician request from all over Pakistan,
with more than 200 collection units located throughout the
country. Moreover, the mycobacteriology laboratory served
as the WHO Supranational Laboratory. Following inception
in 2009 of the National TB-reference Laboratory (NRL), and
later in 2013 as a result of its expansion to perform culture
and drug-susceptibility testing services for clinical manage-
ment of the patients, the number of samples received and
processed at the NRL increased substantially. Therefore, from
2013 to 2015, data from the NRL was also included for MTB.
Laboratory records were retrieved and duplicates removed
for FQ resistance reported among pathogens of interest for
the years 2010–2015. FQ-susceptibility testing for MTB was
performed with the proportion method using ofloxacin
(2 lg/mL) against MTB as recommended by the Clinical Labo-
ratory Institute Standards (CLSI) [7]. MTB H37Rv was used as a
control for each batch of susceptibility testing. Susceptibility
testing of community acquired bacterial pathogens was per-
formed in accordance with CLSI guidelines by disk diffusion
(the Kirby-Bauer method) [8]. Staphylococcus aureus ATCC
25923 and Escherichia coli ATCC 25922 were used as control
organisms.FQ-sales data from Pakistan in total number of grams sold
per year was obtained from IMS Health, Pakistan (IMS Health
Inc., Karachi, Pakistan). The IMS Health database is a multi-
sourced national database that compiles sales data from reg-
istered pharmacies, prescribing physicians, manufacturers,
and wholesalers.
Data were analyzed and bar charts created in MS Excel
(Microsoft Corp., Redmond, WA, USA). Coefficient-of-
regression (r2) values for trends were calculated in MS Excel
(Microsoft Corp.), with an r2P 0.65 representing a significant
trend [9]. Resistance trends were then correlated with FQ-
sales data for MTB and for community pathogens to show a
significant FQ-resistance trend.
To correlate resistance rates with FQ sales, we converted
sales data (from grams sold annually) to defined daily dose
(DDD) per 1000 inhabitants for each year from 2009 to 2014.
DDD conversion was based on 2015 WHO guidelines for
anatomical therapeutic chemical (ATC) classification [10]
and DDD assignment for ciprofloxacin (oral and parenteral),
levofloxacin (oral and parenteral), moxifloxacin (oral and par-
enteral), ofloxacin (oral and parenteral), enoxacin (oral), spar-
floxacin (oral), norfloxacin (oral), pefloxacin (oral), and
gatifloxacin (oral and parenteral). To convert to 1000 inhabi-
tants per year, estimates for the population of Pakistan for
each year were obtained from the World Bank. We also con-
verted resistance data to the logarithm of the odds of resis-
tance (odds = proportion of resistance organisms (p)/1  p;
odds converted to the natural logarithm of the odds). DDD-
log odds resistant pairs were examined with 1-year gaps
(e.g., 2009 DDDs correlated with 2010 resistance rate), given
that previous population-level data showed that the effect
of change in consumption was observed with a lag ofP1 year
[9]. Linear regression (least squares) was then applied to
obtain coefficients of determination (R2) and p values.
The study was exempted from ethical review by the AKU
Ethical Review Committee.
Results
Resistance rates in MTB
During the study period, 18,776 MTB strains were isolated,
including 8492 (45.2%) that wereMDR. The trend in MDR cases
showed a non-significant increase (R2 = 0.4) from 2010 to 2015;
however, a decrease in MDR rates was observed in 2015
(Fig. S1).
FQ-resistance trends in MTB indicated variable rates (an
increase from 2010 to 2011, followed by a consistent rate
and a recent decrease in 2015; all MTB, R2 = 0.1; Fig. 1). Among
non-MDR MTB strains, FQ resistance increased from 10.3%
(n = 214/2059) in 2010 to 16.8% (n = 250/1487) in 2015 (linear
R2 = 0.1), while an insignificant decrease in FQ resistance in
MDR TB was observed from 54.6% (n = 691/1266) in 2010 to
52.3% (n = 591/1129) in 2015 (linear R2 = 0.5).
Resistance rates in community pathogens
Over the 6-year study period, FQ-resistance rates remained
consistently high in Salmonella Typhi and Paratyphi and N.
Fig. 1 – Fluoroquinolone-resistance rates and trends in Pakistan from 2010 to 2015. Coefficients of regression (R2) are shown
for each linear trend.
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in V. cholerae and S. pneumoniae (linear R2 = 0.3; Fig. S2).
However, in H. influenza, FQ resistance increased consis-
tently from 9.1% in 2010 to 29% in 2015 (linear R2 = 0.9), while
in Shigella spp. FQ resistance increased from no detectable
resistance in 2010 to 22% FQ resistance in 2015 (linear
R2 = 0.9). Fig. 1 shows resistance rates and trends in MTB (all
strains, MDR strains, and non-MDR strains), as well as in
H. influenzae and Shigella spp.Fig. 2 – Fluoroquinolone consumption in adult DDDs per
1000 inhabitant days for Pakistan from 2009 to 2014. DDDs
were derived from sales data (in grams sold) by applying the
WHO ATC classification for fluoroquinolones. A rising trend
was observed, albeit a 7% decrease was apparent for 2014.
ATC = anatomical therapeutic chemical; DDD = defined daily
dose; WHO =World Health Organization.Fluoroquinolone-consumption trends
Fluoroquinolone DDDs based on sales from registered phar-
macies are shown in Fig. 2. Sales increased steadily from
2009 to 2013, with a 7% decrease in consumption in 2014. Nev-
ertheless, an increasing trend was observed, with R2 = 0.8.
Correlation of resistance rates with consumption
Linear regression of FQ DDDs per 1000 inhabitant-year and
FQ-resistant MTB (Fig. 3) showed a weak correlation between
increases in consumption and resistance (R2 = 0.2). In con-
trast, regression of H. influenzae and Shigella spp. both showedFig. 3 – Regression of the log odds of fluoroquinolone
resistance in MTB shows a weak correlation (p = 0.18).
MTB =Mycobacterium tuberculosis.
Fig. 4 – Regression of FQ consumption with (A) Haemophilus
influenzae and (B) Shigella spp. resistance rates shows strong
and significant positive correlations. FQ = fluoroquinolone.
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(Fig. 4).Discussion
Density of antibiotic consumption has long been known to
increase drug-resistance rates in a number of microorgan-
isms. In our population, there appeared to be a strong corre-
lation between FQ consumption and increasing resistance
rates in H. influenzae and Shigella spp.; however, for MTB, the
relationship between FQ resistance and consumption was
weak.
While the discrepancy is surprising, there is evidence that
at a population level, MTB does not follow the same model of
resistance emergence and maintenance as other community
organisms [11]. The genetic basis for resistance in MTB is also
unique, as it does not possess plasmids [12]. Furthermore, FQ-
resistance strains have a fitness cost [13] that has not been
correlated with survival and R0 rates in the population. More-
over, the fitness costs may be different for MDR and drug-
sensitive strains [14]. In Taiwan, despite widespread uncon-
trolled use of FQ in the community, from 1995 to 2003, resis-
tance was only observed in MDR strains, indicating that
different triggers (rather than volume of FQ use) are likely to
be responsible for maintenance of FQ resistance in the MTB
resistome [14]. It is hypothesized that at the individual level,especially in MDR patients, FQ resistance is driven by inap-
propriate use of FQ rather than consumption of FQ in the pop-
ulation [14].
We also showed a recent decrease in MTB FQ-resistance
rates. Several improvements at the population level are likely
to have been responsible for this decrease. The National
Tuberculosis Program (NTP) has taken measures to improve
the treatment and care of TB patients in NTP-partner clinics
by enhanced detection [15,16], with adequate treatment of
TB patients achieving up to 88% treatment-success rates
[17], thereby decreasing inappropriate use of FQ among
patients at risk of TB or with active TB. More importantly,
increases in Programmatic Management of Drug-resistant
TB (PMDT) efforts resulted in streamlined second-line treat-
ment regimens [17]. Since we did not observe a proportionate
decrease in FQ resistance in non-MDR strains, the decrease is
likely driven by the upscale of PMDT.
The decline in FQ consumption in 2014 is likely related to
implementation of the Drug Regulatory Authority of Pakistan
(DRAP) Act 2012 [18], which led to a reduction in unregulated
FQ usage; over six brand applications were rejected by DRAP
due to concerns about quality [19,20]. Furthermore, FQ-
consumption data revealed a recent decrease in sales in
2010. This decrease was driven by a decrease in sales of enox-
acin, sparfloxacin, and gatifloxacin, which are more likely to
have been used inappropriately, because they do not find
applications in the mainstream medical community in Pak-
istan. This lends credence to the hypothesis that MTB FQ
resistance is driven by inappropriate FQ usage in the commu-
nity rather than the volume of use and overall selective-
ecological pressure.
Our study had limitations. MTB strains in this study were
recovered from samples from all over Pakistan, while some
data from private laboratories was not available for analysis.
However, the resistance rates shown were representative of
the MDR- and FQ-resistance rates in the country, as data from
the two largest reference centers was included. The con-
sumption data was based on adult and not pediatric dosages,
and, therefore, was only an estimate and not the actual con-
sumed DDD/1000 inhabitant-year. Moreover, our data repre-
sented the population level and, therefore, was prone to
ecological bias. Both individual and population-level data
are required to overcome the inherent bias when correlating
antibiotic consumption with resistance rates [11].
Conclusions
We showed that MTB FQ resistance was unrelated to the vol-
ume of FQ consumption in the community and was more
likely driven by other factors, such as inappropriate use at
the individual level. Prospective ecological studies that com-
bine individual DDDs with MTB FQ resistance are required
to develop a better understanding of drivers of FQ resistance
and ecological antibiotic pressure in MTB.
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